Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1412

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 6
Chunk 1412
---

    36,426,253

    Stockholders’ Deficit

    Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding at December 31, 2024 and 2023

    -

    -

    Common stock; $0.0001 par value; 100,000,000 shares authorized; 2,155,000 issued and outstanding (excluding 164,752 shares subject to possible redemption) at December 31, 2024 and  2,155,000 issued and outstanding (excluding 3,467,954 shares subject to possible redemption) at December 31, 2023

    216

    216

    Additional paid-in capital

    -

    -

    Accumulated deficit

    (8,333,627
    )

    (3,907,008
    )
  
    Total Stockholders’ Deficit

    (8,333,411
    )

    (3,906,792
    )
  
    Total Liabilities and Stockholders’ Deficit
     
    $
    2,303,041

    $
    36,627,733

The accompanying notes are an integral part
of the consolidated financial statements.

F-3

OSR HOLDINGS, INC.

(f/k/a Bellevue Life
Sciences Acquisition Corp.)

CONSOLIDATED
STATEMENTS OF OPERATIONS

    For the Years Ended

    December 31,

    2024

    2023

    EXPENSES

    General and administrative expenses
     
    $
    3,524,549

    $
    1,830,700

    Loss from operations

    (3,524,549
    )

    (1,830,700
    )

    Other income (expense):

    Interest earned on investments held in the Trust Account

    1,450,228

    2,775,291

    Interest income

    2,181

    -

    Interest expense

    (43,011
    )

    -

    Total other income, net

    1,409,398

    2,775,291

    Income (loss) before provision for income taxes

    (2,115,151
    )

    944,591

    Provision for income taxes

    (295,728
    )

    (540,811
    )
  
    NET INCOME (LOSS